Table 1.
Patients clinical and tumor characteristics.
| Clinical factors | Subgroup | N (%) |
|---|---|---|
| Age | <57 | 33 (49.3) |
| ≥57 | 34 (50.7) | |
| Sex | Male | 32 (47.8) |
| Female | 35 (52.2) | |
| Diabetes | Yes | 6 (9.0) |
| No | 61 (91.0) | |
| Autoimmune disease | Yes | 2 (3.0) |
| No | 65 (97.0) | |
| Hypertension | Yes | 19 (28.4) |
| No | 48 (71.6) | |
| Tumor characteristics | Subgroup | N (%) |
| Tumor Site | Sinonasal | 24 (35.8) |
| Others | 43 (64.2) | |
| T Stage | T1 | 5 (7.5) |
| T2 | 15 (22.4) | |
| T3 | 6 (9.0) | |
| T4 | 41 (61.2) | |
| N Stage | N0 | 62 (92.5) |
| N1 | 2 (3.0) | |
| N2 | 3 (4.5) | |
| M Stage | No | 61 (91.0) |
| Lungs | 5 (7.5) | |
| Liver | 1 (1.5) | |
| Surgery before CIRT | Yes | 43 (64.2) |
| No | 24 (35.8) | |
| Margins status at surgical report | RX | 8 (11.9) |
| R1 | 31 (46.3) | |
| R2 | 4 (6.0) | |
| No Surgery | 24 (35.8) | |
| Residual tumor disease (Pre CIRT MRI) | Yes | 30 (44.8) |
| No | 37 (55.2) | |
| Toxicity after CIRT | Subgroup | N (%) |
| Maximum acute toxicity during Follow Up | G0 | 0 (0.0) |
| G1 | 17 (25.4) | |
| G2 | 37 (55.2) | |
| G3 | 13 (19.4) | |
| Acute mucositis | Yes (G1-G4) | 49 (73.1) |
| No (G0) | 18 (26.9) | |
| Maxillary ORN | Yes | 11 (16.4) |
| No | 56 (83.6) |